PAREXEL and the National Taiwan University Hospital (NTUH) have established an alliance to provide drug development services in Taiwan. The alliance aims to drive greater efficiency for biopharma sponsors though NTUH’s center of excellence for clinical trials in Taiwan and the support of PAREXEL’s clinical development services to local and global companies.
“Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of Phase I-IV clinical trials in a rapidly growing market,” said Joe Avellone, M.D., corporate senior vice president, Clinical Research Services, PAREXEL. “The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients' programs in the region and help them to compete more effectively in the global marketplace.”